Wire · opportunities
Freenome secures FDA nod for blood-based colorectal cancer test
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 28 July 2026 · Fusion42 review
Freenome has received FDA clearance for SimpleScreen, a blood-based colorectal cancer screening test that Abbott will distribute in the U.S. The test competes directly with Guardant Health's Shield blood test in the emerging non-invasive CRC screening market.
This Wire brief sits within Fusion42's coverage of Diagnostics, and 4 sources have reported it between 27 Jul 2026 and 28 Jul 2026.
◆ ◆ The Wire takeaway
Abbott now has two colorectal cancer screening options to push into primary care—blood test and stool test—which means the doctors and patients choosing between them will need software to flag which one to order when, and to track results across both modalities. That workflow gap is yours to fill.
◆ Coverage
4 sources · first reported 27 Jul 2026 · latest 28 Jul 2026
◆ Related on Wire
◆ Topics